Avery Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-21.
Avery Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 21, 2026. The filing reports $8.47M sold. Its industry group is Biotechnology. It names Jordan Lancaster (Executive Officer, Director), Lawrence Mehren (Director), Emile Nuwaysir (Director) (SEC Form D, September 21, 2026).
Avery Therapeutics, Inc. raised on Sep 21. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Avery Therapeutics, Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Avery Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Avery Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Avery Therapeutics, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Avery Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Avery Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Avery Therapeutics, Inc. →Get the full cited report on Avery Therapeutics, Inc.
What the filing shows about Avery Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Avery Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Avery Therapeutics, Inc.'s address as 2500 N. Tucson Blvd. Ste. 140, Tucson, AZ 85716.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Avery Therapeutics, Inc. See pricing
Avery Therapeutics, Inc. is a registered filer with the SEC (CIK 1708135) and has filed since 2026-09-21. 1 filing is on record, the latest on 2026-09-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Avery Therapeutics, Inc.'s Form D of 2026-09-21 names Jordan Lancaster, Lawrence Mehren, Emile Nuwaysir and 1 more as its officers, directors or promoters.
Its new offerings report $8.47M sold across 1 offering, as its own filings state.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $8.47M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat diseases and injuries to human muscle. Avery’s lead product, MyCardia™, is being developed to address and treat heart failure.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Jordan Lancaster is named as Executive Officer and Director on the Form D that Avery Therapeutics, Inc. filed with the SEC on 21 September 2026, one of 4 people that filing names.
Lawrence Mehren is named as Director on the Form D that Avery Therapeutics, Inc. filed with the SEC on 21 September 2026, one of 4 people that filing names.
Emile Nuwaysir is named as Director on the Form D that Avery Therapeutics, Inc. filed with the SEC on 21 September 2026, one of 4 people that filing names.
Steven Goldman is named as Executive Officer on the Form D that Avery Therapeutics, Inc. filed with the SEC on 21 September 2026, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2026-09-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Avery Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Avery Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avery Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Avery Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Avery Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-27 (averythera.com).
Each opens in a new tab, filled in for Avery Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-09-21 · Biotech raises, week of 2026-09-21
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/avery-therapeutics-inc-form-d-000003